Treatment Outcomes and Prognostic Factors in Patients with Locally Advanced Cervical Cancer Treated with Definitive Concurrent Chemoradiotherapy: A Four Years Prospective Study in Tash Oncology Center, Addis Abeba, Ethiopia
| dc.contributor.advisor | Sonia Worku | |
| dc.contributor.author | Elsabet Abnew | |
| dc.date.accessioned | 2026-06-18T15:02:22Z | |
| dc.date.available | 2026-06-18T15:02:22Z | |
| dc.date.issued | 2025-12-07 | |
| dc.description.abstract | Background: Locally Advanced Cervical Cancer Continues to Be a Major Cause of Morbidity and Mortality Among Women, With Concurrent Chemoradiation (CCRT) Being the Recommended Treatment for Locally Advanced Disease. However, Prospective Data on Treatment Outcomes and Prognostic Factors Remain Limited in Ethiopia Specially in the LINAC Era. Methods: A Prospective Study of Locally Advanced Cervical Cancer Patients Who Received Definitive CCRT From January 2022 to July 2025 Was Employed. Survival Outcome Was Estimated by Using Kaplan-Meier Curves. Univariant And Multivariant Cox Proportional Model Was Employed to Evaluate the Effect of Various Factors On RR, DFS And OS. Results: Between January 1/2022 and July1/2025, A Total Of 167 Patients Diagnosed with Locally Advanced Cervical Cancer Managed with Curative-Intent Radiotherapy Were Enrolled. The Median Age of Patients Was 53.5 Year (IQR 45–62). In This Study 66.5% Of Patients Received A Brachytherapy Boost While an EBRT Boost Was Used In 18.5% Of Cases. Concurrent Chemotherapy Was Administered In 64.5% Of Patients. Of 167 Patients, 118 (70.7%) Achieved Complete Response (CR) At 3 Months. Among The 118 Patients Analyzed, 69.5% Experienced No Recurrence During the Follow-Up Period. Recurrence Was Observed In 30.5%. The 2-Year Overall Survival (OS) Was 73%, And The 2-Year Disease Free Survival (DFS) Was 71% Based on the Kaplan–Meier Estimates. Late Radiation-Induced Adverse Events Were Documented In 82 Patients (49.1%). No Late Toxicity Was Reported For 59 Patients (35.3%), While the Status Was Unknown or Not Assessable For 26 Patients (15.6%). Conclusion: This Prospective Study Shows That Definitive Radiotherapy with Concurrent Chemotherapy and Brachytherapy Provides Clinically Meaningful Response Rates, Survival Outcomes, And Manageable Toxicity Profiles for Patients with Locally Advanced Cervical Cancer Treated at Tikur Anbesa Specialized Hospital in the LINAC Era. The Observed Two-Year Overall and Disease-Free Survival Rates Align with Existing Evidence Supporting of Concurrent Chemoradiotherapy as the Standard of Care in This Setting. | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/8225 | |
| dc.language.iso | en | |
| dc.publisher | Addis Ababa University | |
| dc.subject | Locally advanced cervical cancer | |
| dc.subject | Concurrent chemoradiotherapy | |
| dc.subject | Recurrence or metastasis | |
| dc.subject | Prognostic factors | |
| dc.title | Treatment Outcomes and Prognostic Factors in Patients with Locally Advanced Cervical Cancer Treated with Definitive Concurrent Chemoradiotherapy: A Four Years Prospective Study in Tash Oncology Center, Addis Abeba, Ethiopia | |
| dc.type | Thesis |